Home > Insider Trading > Filing (0001562180-20-001936)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1517022	Akebia Therapeutics Inc.	AKBA	Pharmaceutical Preparations (2834)	208756903

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1602396	R. Nicole Hadas	C/O Akebia Therapeutics, Inc. 245 First Street Cambridge MA 02142	Svp, Chief Legal Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-02-28	62,000	$0.00	219,806	No	4	A	Direct
Common Stock	Disposition	2020-02-28	7,050	$8.70	212,756	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to buy)	Acquisiton	2020-02-28	105,000	$0.00	105,000	$8.87

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
105,000		2030-02-28	No	4	A	Direct

Footnotes

The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date.
Includes 1,500 shares of the Issuer's common stock purchased on June 28, 2019 and 1,500 shares of the Issuer's common stock purchased on December 31, 2019, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan.
This sale was made to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019.
The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.